Anemia

Hematology
85
Pipeline Programs
18
Companies
50
Clinical Trials
3 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
3
35
0
29
14
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1292%
Peptide
18%
+ 74 programs with unclassified modality

On Market (4)

Approved therapies currently available

Amgen
ARANESPApproved
darbepoetin alfa
Amgen
Erythropoiesis-stimulating Agent [EPC]subcutaneous2001
U
INJECTAFERApproved
ferric carboxymaltose injection
Unknown Company
intravenous2013
U
MIRCERAApproved
methoxy polyethylene glycol-epoetin beta
Unknown Company
injection2007
Akebia Therapeutics
VAFSEOApproved
vadadustat
Akebia Therapeutics
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]oral2024

Competitive Landscape

18 companies ranked by most advanced pipeline stage

OD
19 programs
14
4
1
Epoetin AlfaPhase 4
Epoetin alfaPhase 3
epoetin alfaPhase 3
epoetin alfaPhase 3
epoetin alfaPhase 3
+14 more programs
Akebia Therapeutics
Akebia TherapeuticsCAMBRIDGE, MA
14 programs
8
6
1
VadadustatPhase 3Small Molecule1 trial
VadadustatPhase 3Small Molecule1 trial
VadadustatPhase 3Small Molecule1 trial
VadadustatPhase 3Small Molecule1 trial
VadadustatPhase 3Small Molecule1 trial
+9 more programs
Active Trials
NCT01906489CompletedEst. Sep 2014
NCT01381094CompletedEst. Feb 2012
NCT02260193CompletedEst. Jul 2015
+11 more trials
Roche
RocheSTAVANGER NORWAY, Norway
13 programs
1
9
3
Epoetin BetaPhase 41 trial
Epoetin betaPhase 45 trials
methoxy polyethylene glycol-epoetin beta [Mircera]Phase 41 trial
Darbepoetin alfaPhase 31 trial
Epoetin alfa or betaPhase 31 trial
+8 more programs
Active Trials
NCT00360347CompletedEst. Apr 2003
NCT00605345Completed71Est. Jul 2009
NCT00077610Completed673Est. Aug 2005
+14 more trials
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
11 programs
5
4
1
Epoetin AlfaPhase 41 trial
epoetin alfaPhase 31 trial
epoetin alfaPhase 31 trial
epoetin alfaPhase 31 trial
epoetin alfaPhase 31 trial
+6 more programs
Active Trials
NCT00834691Completed180
NCT00240734Terminated11Est. Sep 2005
NCT00210600Completed186Est. Aug 2006
+8 more trials
Amgen
AmgenTHOUSAND OAKS, CA
10 programs
1
2
4
3
Aranesp®Phase 45 trials
PeginesatidePhase 4Peptide1 trial
darbepoetin alfaPhase 41 trial
ARANESP(Darbepoetin Alfa)Phase 35 trials
Darbepoetin alfaPhase 31 trial
+5 more programs
Active Trials
NCT01428154Withdrawn0Est. Nov 2016
NCT00035607Completed120Est. Apr 2003
NCT00989092Terminated287Est. Jun 2004
+15 more trials
Takeda
TakedaTOKYO, Japan
2 programs
1
DynepoPhase 42 trials
DYNEPON/A1 trial
Active Trials
NCT00664066Terminated3Est. Jul 2008
NCT00514813Terminated152Est. Jul 2008
NCT00450333Terminated407Est. Jul 2008
Verona Pharma
Verona PharmaUK - London
1 program
1
Ferric Carboxymaltose InjectionPhase 41 trial
Active Trials
NCT05505006Unknown500Est. Aug 2024
Alliance Pharmaceuticals
2 programs
1
1
epoetin alfaPhase 32 trials
cyclosporinePhase 21 trial
Active Trials
NCT00031980Completed30Est. May 2005
NCT00058331Completed365Est. May 2006
NCT00003600Completed344Est. Jan 2010
CP
Chugai PharmaJapan - Tokyo
1 program
1
epoetin betaPhase 31 trial
Active Trials
NCT00628043Completed160Est. Sep 2009
M&
Merck & Co.RAHWAY, NJ
3 programs
3
MK2578Phase 21 trial
MK2578 1mcg for every 600 UnitsPhase 21 trial
SotaterceptPhase 25 trials
Active Trials
NCT00968617Terminated7Est. May 2010
NCT00924781Terminated39Est. May 2010
NCT06351345Recruiting14Est. Feb 2030
+4 more trials
Bayer
BayerLEVERKUSEN, Germany
2 programs
1
1
BAY85-3934Phase 21 trial
BAY85-3934Phase 15 trials
Active Trials
NCT04899661Active Not Recruiting1,081Est. Sep 2027
NCT03543657Completed229Est. Dec 2019
NCT03418168Completed51Est. Jul 2019
+3 more trials
Cook Medical
Cook MedicalIN - Bloomington
1 program
1
Epoetin AlfaPhase 21 trial
Active Trials
NCT00337441UnknownEst. Jul 2005
Knight Therapeutics
Knight TherapeuticsQC - Montréal
2 programs
1
EntospletinibPhase 1/2Small Molecule1 trial
Weekly procrit dosingN/A1 trial
Active Trials
NCT00258440Terminated7Est. Sep 2008
NCT03010358Completed24Est. Apr 2021
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
COR-001Phase 1/21 trial
Active Trials
NCT02868229Completed61Est. Dec 2018
Velico Medical
Velico MedicalMA - Beverly
1 program
1
A-ECOPhase 11 trial
Active Trials
NCT00261274Completed
Astellas
AstellasChina - Shenyang
1 program
1
roxadustatPhase 1Small Molecule1 trial
Active Trials
NCT01083888Completed12Est. Jun 2010
AT
Agile TherapeuticsNJ - Princeton
2 programs
Minayo Iron-rich Nutritional GummiesN/A1 trial
Minayo Yeast Drink ProductN/A1 trial
Active Trials
NCT06869824Completed36Est. Apr 2025
NCT06066151Completed11Est. Dec 2023
CSL Behring
CSL BehringIL - Bradley
1 program
Data collection on interventions performs as per medical routineN/A1 trial
Active Trials
NCT06878105Recruiting2,000Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
RocheEpoetin beta
Merck & Co.Sotatercept
Merck & Co.Sotatercept
Verona PharmaFerric Carboxymaltose Injection
AmgenPeginesatide
Rochemethoxy polyethylene glycol-epoetin beta [Mircera]
RocheEpoetin beta
RocheEpoetin beta
RocheEpoetin beta
RocheEpoetin beta
RocheEpoetin beta
RocheEpoetin beta
RocheEpoetin beta
TakedaDynepo
RocheEpoetin beta

Showing 15 of 45 trials with date data

Clinical Trials (50)

Total enrollment: 17,116 patients across 50 trials

NCT00117065AmgenAranesp®

Study of Transplant Related Anemia Treated With Aranesp® (STRATA)

Phase 4Completed
NCT00117104AmgenAranesp®

Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis

Phase 4Completed
NCT00117078AmgenAranesp®

Aranesp® Monthly Preference Study - 2

Phase 4Completed
NCT00413101RocheEpoetin beta

A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.

Est. completion: Mar 200850 patients
Phase 4Completed
NCT07140484Merck & Co.Sotatercept

Sotatercept in Pulmonary Arterial Hypertension

Start: Oct 2025Est. completion: Jan 2030
Phase 4Recruiting
NCT06658522Merck & Co.Sotatercept

Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)

Start: May 2025Est. completion: May 202620 patients
Phase 4Recruiting
NCT05505006Verona PharmaFerric Carboxymaltose Injection

Management of Preoperative Anaemia in Surgical Oncology

Start: Mar 2021Est. completion: Aug 2024500 patients
Phase 4Unknown
NCT01737879AmgenPeginesatide

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

Start: Oct 2012Est. completion: Jul 201341 patients
Phase 4Terminated
NCT01342640Rochemethoxy polyethylene glycol-epoetin beta [Mircera]

A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia

Start: Jul 2011Est. completion: Nov 201270 patients
Phase 4Completed
NCT01066000RocheEpoetin beta

A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia

Start: Oct 2009Est. completion: Sep 201133 patients
Phase 4Terminated
NCT00922116RocheEpoetin beta

A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis

Start: Apr 2009Est. completion: Nov 2010191 patients
Phase 4Completed
NCT00922610RocheEpoetin beta

A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients

Start: Feb 2009Est. completion: Jul 201028 patients
Phase 4Completed
NCT00773513RocheEpoetin beta

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Start: Dec 2008Est. completion: Jul 20172,825 patients
Phase 4Completed
NCT00737464RocheEpoetin beta

A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Start: Aug 2008Est. completion: Sep 2009132 patients
Phase 4Completed
NCT00642668RocheEpoetin beta

A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia

Start: Jun 2008Est. completion: Dec 200935 patients
Phase 4Completed
NCT00560274RocheEpoetin beta

A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.

Start: Mar 2008Est. completion: Nov 2011190 patients
Phase 4Completed
NCT00514813TakedaDynepo

Dynepo Long-Term Safety Study

Start: Jun 2007Est. completion: Jul 2008152 patients
Phase 4Terminated
NCT00776425RocheEpoetin beta

A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies

Start: Jan 2007Est. completion: Nov 2012117 patients
Phase 4Completed
NCT02608060RocheEpoetin Beta

A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B

Start: Sep 2006Est. completion: Oct 20074 patients
Phase 4Terminated
NCT02624141RocheEpoetin beta

A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy

Start: Apr 2006Est. completion: Dec 200910 patients
Phase 4Terminated
NCT02564094RocheEpoetin beta

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies

Start: Feb 2005Est. completion: Jun 200654 patients
Phase 4Completed
NCT00117039AmgenAranesp®

A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia

Start: Jan 2004Est. completion: Apr 20051,500 patients
Phase 4Completed
NCT00153868Amgendarbepoetin alfa

A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer

Start: Oct 2003Est. completion: Aug 200743 patients
Phase 4Completed
NCT00122720AmgenDarbepoetin Alfa

The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery

Start: Jun 2003Est. completion: Jan 2006200 patients
Phase 4Completed
NCT00117117AmgenAranesp®

A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

Start: Sep 2002Est. completion: Dec 20032,423 patients
Phase 4Completed
NCT00369733AmgenDarbepoetin Alfa

STAAR-3 Clinical Study

Start: May 2002Est. completion: May 2004443 patients
Phase 4Completed
NCT00111995AmgenAranesp®

Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis

Start: May 2002400 patients
Phase 4Completed
NCT00211120Johnson & JohnsonEpoetin Alfa

Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)

Start: Mar 2002Est. completion: Aug 20051,432 patients
Phase 4Terminated
NCT00369772AmgenDarbepoetin Alfa

STAAR-1 Clinical Study

Start: Feb 2002Est. completion: May 20042,000 patients
Phase 4Completed
NCT00368901AmgenDarbepoetin Alfa

STAAR-2 Clinical Study

Start: Jan 2002Est. completion: May 2004618 patients
Phase 4Completed
NCT00148421AmgenDarbepoetin Alfa

Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.

Phase 3Completed
NCT00124098AmgenDarbepoetin Alfa

An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)

Phase 3Completed
NCT07218029Merck & Co.Sotatercept

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

Start: May 2021Est. completion: Dec 2028815 patients
Phase 3Recruiting
NCT04313153Akebia TherapeuticsVadadustat

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Start: May 2020Est. completion: Jun 2022319 patients
Phase 3Completed
NCT03543657BayerBAY85-3934

Maintenance Treatment of Renal Anemia in Dialysis Subjects

Start: Jun 2018Est. completion: Dec 2019229 patients
Phase 3Completed
NCT03418168BayerBAY85-3934

A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects

Start: Feb 2018Est. completion: Jul 201951 patients
Phase 3Completed
NCT03351166BayerBAY85-3934

A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects

Start: Jan 2018Est. completion: Nov 201825 patients
Phase 3Completed
NCT03350347BayerBAY85-3934

A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects

Start: Dec 2017Est. completion: Nov 2019164 patients
Phase 3Completed
NCT03350321BayerBAY85-3934

A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects

Start: Dec 2017Est. completion: Oct 2019162 patients
Phase 3Completed
NCT03242967Akebia TherapeuticsVadadustat

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Start: Aug 2017Est. completion: Feb 2018
Phase 3Withdrawn
NCT02892149Akebia TherapeuticsVadadustat

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Start: Aug 2016Est. completion: Mar 2020
Phase 3Completed
NCT02865850Akebia TherapeuticsVadadustat

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Start: Jul 2016Est. completion: Mar 2020
Phase 3Completed
NCT02680574Akebia TherapeuticsVadadustat

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Start: Feb 2016Est. completion: Jul 2020
Phase 3Completed
NCT02648347Akebia TherapeuticsVadadustat

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Start: Dec 2015Est. completion: Jul 2020
Phase 3Completed
NCT01652872AmgenDarbepoetin Alfa

Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Start: Jul 2012Est. completion: Oct 2017756 patients
Phase 3Completed
NCT01362140AmgenDarbepoetin Alfa

Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Start: Dec 2011Est. completion: Sep 2017147 patients
Phase 3Completed
NCT00773331RocheEpoetin beta

A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.

Start: Jul 2009Est. completion: Dec 2010281 patients
Phase 3Completed
NCT00925587AmgenDarbepoetin Alfa

Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

Start: Jun 2009Est. completion: May 2012358 patients
Phase 3Completed
NCT00882713Rochemethoxy polyethylene glycol-epoetin beta [Mircera]

A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia

Start: Feb 2009Est. completion: Oct 2010202 patients
Phase 3Completed
NCT00737477RocheEpoetin beta

A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis

Start: Sep 2008Est. completion: Jul 201196 patients
Phase 3Completed

Related Jobs in Hematology

MSL Hematología L - Sur

Johnson & Johnson
Sevilla, Spain
Yesterday

Sr. Director Marketing

Genetix Biotherapeutics
Somerville, Massachusetts, United States
4d ago

Specialty Care Field Medical Director, Sickle Cell Disease, non-MD

Pfizer
Remote
1w ago

Disease Area Squad Lead Hemophilia

Roche
Algeria
1w ago

Specialty Care Field Medical Director, Sickle Cell Disease, MD

Pfizer
Remote
1w ago

Clinical Trial Manager

Fulcrum Therapeutics
Cambridge, MA
3w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

29 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 17,116 patients
18 companies competing in this space

Related Indications

Myelofibrosis(21)Polycythemia Vera(16)Primary Immune Thrombocytopenia(15)Primary Myelofibrosis(14)Immune Thrombocytopenia(12)Thrombocytopenia(11)Beta-Thalassemia(10)Aplastic Anemia(7)Anemia of Chronic Kidney Disease(7)Iron Deficiency Anemia(6)